Month: September 2026

FAST TRACK GROUP Announces Delisting of Ordinary Shares from The Nasdaq Capital Market; Securities to Remain Trading on the OTC Markets

Posted on by Ravi Shankar

SINGAPORE, Sept. 23, 2026 (GLOBE NEWSWIRE) — FAST TRACK GROUP (OTC: FTRKD) (the “Company”), a leading entertainment-focused event management and celebrity agency company, announced that The Nasdaq Stock Market LLC (“Nasdaq”) will delist the Company’s Class A ordinary shares (the “Shares”) from The Nasdaq Capital Market. Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the “SEC”) to complete the delisting, which will become effective ten days after the Form 25-NSE is filed.

On August 11, 2026, the Company received a determination letter from Nasdaq’s Listing Qualifications Department based on the Company’s failure to satisfy the US$1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Trading of the Shares on Nasdaq was suspended at the opening of business on August 18, 2026. The Company requested a hearing before a Nasdaq Hearings Panel under the Nasdaq Rule 5800 Series, and on September 15, 2026, the company withdrew its appeal on the Staff’s determination. As a result the Hearing before a Panel that was scheduled on September 17, 2026 was cancelled.

On September 17, 2026, Nasdaq announced that it will file a Form 25-NSE with the SEC to complete the delisting of the Company’s Class A ordinary shares from Nasdaq. The delisting will become effective ten days after the Form 25-NSE is filed. 

The Shares have been quoted on the OTC Markets under the symbol “FTRKF” since August 18, 2026, and temporarily as “FTRKD” for twenty business days following the recent 1-for-20 reverse split. The Shares are expected to continue trading on the OTC Markets following the Nasdaq delisting. The Company will remain a reporting company under the U.S. Securities Exchange Act of 1934, as amended, and intends to continue filing its annual report on Form 20-F and furnishing reports on Form 6-K with the SEC.

About FAST TRACK GROUP
FAST TRACK GROUP (OTC: FTRKD) is a leading entertainment-focused event management and celebrity agency company. Since inception in Singapore in 2012, the Company has expanded across Asia Pacific, earning a reputation for being the preferred partner for event and endorsement organizers in the region. FAST TRACK GROUP goes beyond traditional event management, offering value-added services such as technical production planning, celebrity sourcing, celebrity engagement consultancy and event manpower support, all tailored to the highest standards.

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results. It encourages investors to read the risk factors contained in the Company’s final prospectus, and other reports it files with the SEC, before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law.

Investor Relations Contact
Gateway Group, Inc.
949-574-3860
FTRK@gateway-grp.com

Posted in UncategorizedTagged

Asset Portfolio Briefing: First Gold Production at Cuiú Cuiú, Imminent Gold Production at Amulsar, and Other Positive Updates

Posted on by Ravi Shankar

MONTRÉAL, Sept. 23, 2026 (GLOBE NEWSWIRE) — OR Royalties Inc. (“OR Royalties,” or the “Company”) (OR: TSX & NYSE) is pleased to provide the following select producing, development and exploration asset updates. Amounts presented are in United States dollars, except where otherwise noted.

Select Producing Asset Update Summaries

For additional details on select royalties and streams, please refer to OR Royalties’ 2026 Asset Handbook (link)

  • Cuiú Cuiú (Cabral Gold Inc. (“Cabral”)) – First gold produced at Cuiú Cuiú on September 10, 2026, with mine ramp-up to commercial production expected in the fourth quarter of 2026. A recent C$45 million strategic investment by Alpayana S.A.C. into Cabral will help accelerate the Phase 1 oxide mine, as well as development work on the conceptual Phase 2 hard-rock gold project. OR Royalties owns a 1.0% net smelter return (“NSR”) royalty on Cuiú Cuiú.
  • Amulsar (United Gold) – First gold production at Amulsar is imminent with the mine’s ramp-up toward commercial production still on track for the first half of 2027. OR Royalties, through its wholly-owned subsidiary OR Royalties International Ltd. (“ORI”), owns a gold stream and a silver stream on Amulsar. ORI will purchase (i) refined gold (“Au”) equal to 3.34% of payable Au produced from the mine until delivery of ~82.3 thousand ounces (“koz”) Au (1.31% of payable Au thereafter), and (ii) refined silver (“Ag”) equal to 49.22% of payable Ag produced from the mine until delivery of ~1.03 million ounces (“Moz”) Ag (19.69% of payable Ag thereafter). First stream payments to ORI under the Au and Ag streams are expected late 2027, or the first half of 2028 (Au and Ag price dependent).
  • CSA (Harmony Gold Mining Company Limited (“Harmony”)) – Harmony provided Financial Year 2027 (“FY27”) CSA copper production guidance of 28-30 thousand tonnes (“kt”) copper (“Cu”). Harmony is targeting a production run rate of 40kt Cu per annum by FY29. An updated Mineral Reserve Estimate increased contained copper inventory when compared to the previous Mineral Reserve Estimate. ORI currently owns a 100% Ag stream and a 3.0% Cu stream at CSA.
  • Dalgaranga (Ramelius Resources Limited) – Underground mined tonnage and grades continue to increase: the June 2026 Quarter saw a total of 115kt of ore mined at an average grade of 5.95 grams per tonne (“g/t”) Au from the Never Never underground mine. OR Royalties owns a 1.44% gross revenue (“GR”) royalty on Dalgaranga and a 1.08% GR royalty on some regional tenements (including the Melville project, where OR Royalties owns an additional 1.0% NSR royalty).
  • Bralorne (Talisker Resources Ltd. (“Talisker”)) – In late August, Talisker reported the successful loading and departure of its first ore shipment to Taiwan as part of Talisker’s direct shipping ore strategy at Bralorne. As of August 31, 2026, Bralorne has produced approximately 4.9koz Au from 19,014 tonnes mined at an average grade of 7.99 g/t Au. Results from the Bralorne preliminary economic assessment (“PEA”) were released on September 21, 2026 and contemplated a gradual ramp-up in production during a four-year permitting and construction period, during which rates grow from about 350 tonnes per day (“tpd”) to 1,500tpd at the start of mill commissioning. Following the start of commercial production, the mining rate increases up to a maximum of 2,875tpd for an average of 2,700tpd over the next 14 years. Average annual gold production from the start of mill commissioning in 2031 is expected to be 110koz. OR Royalties owns a 1.7% NSR royalty on Bralorne and the surrounding property. OR Royalties received its first royalty payment from Talisker in April 2025.

Select Development Asset Update Summaries

  • Cariboo (Osisko Gold Group Inc. (“OGG”)) – September 14, 2026 announcement of positive formal construction decision on the Cariboo Gold Project made by OGG’s Board of Directors, with first gold pour expected in the first quarter of 2029 and commercial production in the second half of 2029. OGG also provided a go-forward capital obligation update for Cariboo of C$990 million, supported by total available and proposed estimated sources of capital of up to C$1,637 million, including C$837 million in cash & equivalents as of September 14, 2026. OR Royalties owns a 5.0% NSR royalty on Cariboo.
  • Windfall (Gold Fields Limited (“Gold Fields”)) – Early June signing of the Impact Benefit Agreement with the Cree First Nation of Waswanipi and the Cree Nation Government and the Grand Council of the Crees (Eeyou Istchee). Gold Fields continues to await a recommendation for the issuance of the Environmental Impact Assessment (“EIA”) from the Environmental and Social Impact Review Committee of Québec. Based on engagements with the Government of Québec and the Cree Nation Government, EIA approval is still expected in the second half of 2026, followed by first production in the first half of 2029. OR Royalties owns a 2.0-3.0% NSR royalty on the Windfall project and the surrounding property.
  • Hermosa/Taylor (South32 Ltd.) – The US Forest Service released the Final Record of Decision (“ROD”) for the “Hermosa Critical Minerals Project”, which completes the federal National Environmental Policy Act (“NEPA”) process needed for Hermosa’s ancillary infrastructure development on National Forest Service land following years of environmental study. First production from the Taylor zinc-lead-silver deposit scheduled for the first half of 2028. Zinc prices are currently trading close to four-year highs. OR Royalties owns a 1.0% NSR royalty on zinc and lead sulfide ores produced at Hermosa.
  • South Railroad (Equinox Gold Corp.) – The United States Bureau of Land Management has issued a positive ROD for the South Railroad project in Nevada, marking completion of federal permitting under the NEPA process. With the ROD now issued, early works construction at South Railroad has begun; first production is scheduled for the first half of 2028. ORI owns a 100% Ag stream at South Railroad.
  • San Antonio (Axo Metals Corp.) – The Mexican Federal Environmental Department issued a positive decision approving the Environmental Impact Statement for the San Antonio gold project located in the State of Sonora. This landmark approval grants the primary authorization required for the construction and operation of the mine. ORI owns a 7.15% precious metals stream (Au and Ag) at San Antonio.
  • White Pine North (White Pine Copper LLC (“WPC”)) – September 21, 2026 announcement of Pre-Feasibility Study results from White Pine North (“WPN”), including a Probable Mineral Reserve of 137.9 million tonnes (“Mt”) grading 1.04% Cu and 16.02 g/t Ag, and a 26-year mine plan with steady-state production of 5.4Mt of ore per year and more than 45kt of payable Cu per year. All major permit applications have been submitted for review by the Michigan Department of Environment, Great Lakes, and Energy. WPC is targeting a Final Investment Decision in the second half of 2027 and commercial production in 2030. OR Royalties currently owns a 1.5% NSR royalty on Cu production from WPN. OR Royalties also currently owns a sliding scale royalty on silver production at WPN at a rate of 12.5% which increases to 15% at a copper price at or above $4.50 per pound Cu and further increases by 5% for every $0.075 per pound increment in copper price to a maximum of 100%.
  • Eagle (PricewaterhouseCoopers (“Receiver”)) – The Receiver confirmed in early July that the exclusivity period would be extended by an additional 90 days to allow Boroo Pte Ltd. to continue its due diligence, negotiate the terms of a potential purchase agreement and continue discussions with the Yukon Government and the First Nation of Na-Cho Nyäk Dun on the key agreements required for the sale of the Eagle Gold Mine to proceed. OR Royalties owns a 5.0% NSR royalty on Eagle.

Select Exploration Asset Update Summaries

  • Glenburgh (Benz Mining Corp. (“Benz”)) – Closing of an A$150 million private placement to accelerate the current 450,000-metre (“m”) drill program; an initial Mineral Resource Estimate is targeted for the first half of 2027. Benz has outlined an Exploration Target of 10.1-12.0Moz contained gold. OR Royalties owns a 1.08% GR royalty on Glenburgh, which also extends over Mt Egerton.
  • Ritz (Torque Metals Limited) – Reported high-grade RC drilling assay results from the HHH deposit at Ritz; notably, 11.0m grading 456.0 g/t Au from 122.0m down hole. OR Royalties owns a 2.0% NSR royalty on Ritz (formerly Paris).
  • Woodjam (Vizsla Copper Corp.) – Drilling intersected intervals of strong porphyry-related mineralization at the Deerhorn deposit: 266.0m of 0.97% Cu, 0.06 g/t Au, and 4.29 g/t Ag from 306.0m down hole; including 48.5m of 3.32% Cu, 0.23 g/t Au, and 16.59 g/t Ag from 320.5m down hole. OR Royalties owns a 2.0% NSR royalty on Woodjam.
  • Shovelnose (Westhaven Gold Corp. (“Westhaven”)) – Westhaven reported highlight drillhole assay results including 10.0m grading 12.2 g/t Au and 103.0 g/t Ag located below the proposed mine development in the 2025 Shovelnose PEA. OR Royalties owns a 2.0% NSR royalty on Shovelnose.
  • Japan Gold Portfolio (Japan Gold Corp. (“JPG”)) – September 23, 2026 announcement regarding the formation of a strategic alliance with Solidcore Resources plc (“Solidcore”), whereby Solidcore has committed to funding $35 million on five initial areas of the JPG portfolio. OR Royalties has agreed to exercise its right to acquire an additional 0.5% royalty on all properties in consideration for $3 million, resulting in the increase of its existing royalty interest from 1.5% to 2.0%.

Jason Attew, President & CEO of OR Royalties, commented: “Our partners showed no signs of slowing down over the past few months, with many positive updates having surfaced across our asset portfolio over the same period. First, congratulations to Cabral on getting Cuiú Cuiú into production, and congratulations to the team at United Gold for being on the cusp of the same incredible achievement at Amulsar; we look forward to the operational ramp-ups at both new mines and the resulting GEOs delivered to OR Royalties.

“Our February 2026 acquisition of the Gold Fields royalty portfolio continues to pay dividends: production at Buenaventura’s San Gabriel mine in Peru continues to ramp up, while some of the royalties acquired on earlier-stage assets in that portfolio, such as Ritz and Woodjam, are benefitting from some extraordinary exploration results. Separately, with additional equity financing recently secured, Benz Mining is accelerating its 450,000m exploration program at Glenburgh, one of the largest exploration programs of its kind in the world.

“Finally, ample positive portfolio catalysts are expected before year-end 2026, including material updates from Canadian Malartic, Mantos Blancos, and Island Gold, amongst others.”

Sources for Technical Information:

Cuiú Cuiú

Amulsar

CSA

Dalgaranga

Bralorne

Cariboo

Windfall

Hermosa

South Railroad

San Antonio

White Pine North

Eagle

Glenburgh

Ritz

Woodjam

Shovelnose

Japan Gold Portfolio


Qualified Person

The scientific and technical content of this news release has been reviewed and approved by Guy Desharnais, Ph.D., P.Geo., Vice President, Project Evaluation at OR Royalties Inc., who is a “qualified person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

About OR Royalties Inc.

OR Royalties is a precious metals royalty and streaming company focused on Tier-1 mining jurisdictions defined as Canada, the United States, and Australia. OR Royalties commenced activities in June 2014 with a single producing asset, and today holds a portfolio of over 200 royalties, streams and similar interests. OR Royalties’ portfolio is anchored by its cornerstone asset, the 3-5% net smelter return royalty on Agnico Eagle Mines Ltd.’s Canadian Malartic Complex, one of the world’s largest gold mines.

OR Royalties’ head office is located at 1100 Avenue des Canadiens-de-Montréal, Suite 300, Montréal, Québec, H3B 2S2.

For further information, please contact OR Royalties Inc.:
Grant Moenting
Vice President, Capital Markets
Cell: (365) 275 1954
Email: gmoenting@ORroyalties.com		 Heather Taylor
Vice President, Sustainability and Communications
Tel: (647) 477 2087
Email: htaylor@ORroyalties.com


Forward-Looking Statements

Certain statements contained in this press release may be deemed “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking statements are statements other than statements of historical fact, that address, without limitation, future events, that exploration, development and growth catalysts announced by operators of the properties in which the Company holds an interest will be achieved as planned and in a timely manner, that additional material updates on Canadian Malartic, Mantos Blancos and Island Gold will be provided by the respective operators in a timely manner and that such catalysts and updates will continue to positively impact OR Royalties. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential”, “scheduled” and similar expressions or variations (including negative variations), or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors, most of which are beyond the control of OR Royalties, and actual results may accordingly differ materially from those in forward-looking statements. Such risk factors include, without limitation, (i) with respect to properties in which OR Royalties holds a royalty, stream or other interest (collectively an “Interest”), risks related to: (a) the operators of the properties, (b) timely development, permitting, construction, commencement of production, ramp-up (including operating and technical challenges), (c) differences in rate and timing of production from Mineral Resource Estimates or production forecasts by operators, (d) differences in conversion rate from Mineral Resources to Mineral Reserves and ability to replace Mineral Resources, (e) the unfavorable outcome of any challenges or litigation relating to title, permit or license, (f) hazards and uncertainty associated with the business of exploration, development and mining including, but not limited to unusual or unexpected geological and metallurgical conditions, slope failures or cave-ins, flooding and other natural disasters or civil unrest or other uninsured risks, (ii) with respect to other external factors: (a) fluctuations in the prices of the commodities that drive royalties, streams, offtakes and investments held by OR Royalties, (b) a trade war or new tariff barriers, (c) fluctuations in the value of the Canadian dollar relative to the U.S. dollar, (d) regulatory changes by national and local governments, including permitting and licensing regimes and taxation policies, regulations and political or economic developments in any of the countries where properties in which OR Royalties holds an Interest are located or through which they are held, (e) continued availability of capital and financing and general economic, market or business conditions, and (f) responses of relevant governments to infectious disease outbreaks and the effectiveness of such response and the potential impact of such outbreaks on OR Royalties’ business, operations and financial condition; (g) geopolitical instability; (iii) with respect to internal factors: (a) business opportunities that may or may not become available to, or are pursued by OR Royalties, (b) the integration of acquired assets or (c) the determination of OR Royalties’ PFIC status. The forward-looking statements contained in this press release are based upon assumptions management believes to be reasonable, including, without limitation: the absence of significant change in OR Royalties’ ongoing income and assets relating to determination of its PFIC status, and the absence of any other factors that could cause actions, events or results to differ from those anticipated, estimated or intended and, with respect to properties in which OR Royalties holds an Interest, (i) the ongoing operation of the properties by the owners or operators of such properties in a manner consistent with past practice and with public disclosure (including forecast of production), (ii) the accuracy of public statements and disclosures made by the owners or operators of such underlying properties (including expectations for the development of underlying properties that are not yet in production), (iii) no adverse development in respect of any significant property, (iv) that statements and estimates relating to mineral reserves and resources by owners and operators are accurate and (v) the implementation of an adequate plan for integration of acquired assets.

For additional information on risks, uncertainties and assumptions, please refer to the most recent Annual Information Form of OR Royalties filed on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov which also provides additional general assumptions in connection with these statements. OR Royalties cautions that the foregoing list of risks and uncertainties is not exhaustive. Investors and others should carefully consider the above factors as well as the uncertainties they represent and the risk they entail. OR Royalties believes that the assumptions reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be accurate as actual results and prospective events could materially differ from those anticipated in such forward-looking statements and such forward-looking statements included in this press release are not a guarantee of future performance and should not be unduly relied upon. In this press release, OR Royalties relies on information publicly disclosed by other issuers and third parties pertaining to its assets and, therefore, assumes no liability for such third-party public disclosure. These statements speak only as of the date of this press release. OR Royalties undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by applicable law.

Posted in UncategorizedTagged

SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar

Posted on by Ravi Shankar

NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that SRX Global’s CEO, Kent Cunningham, and President, EMJX Platform and Head of Asset Management, Eric Jackson, will present at the Webull Corporate Connect Series Fintech Investment Webinar, a live investor webinar hosted on the Webull platform, on September 30, 2026.

Webull Corporate Connect Series Fintech Investment Webinar
Date: Wednesday, September 30, 2026
Time: 1:00 p.m. ET
Speakers: Kent Cunningham, CEO, SRX Global Inc., Eric Jackson, President, EMJX Platform and Head of Asset Management

Interested parties may register for the webinar at webull.com/webinar. Registration is also available directly within the Webull mobile app. A Webull account is required to register and to access the live session; account setup is free and available to the public.

A replay of the webinar will be available on the Webull platform.

About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “intend,” “aim,” “plan,” “may,” “could,” “target,” and similar expressions are intended to identify forward-looking statements, including statements regarding the timing, format, and content of the referenced webinar. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks described in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

Company Contact
SRX Global Inc.
Kent Cunningham, Chief Executive Officer

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com 

Posted in UncategorizedTagged

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

Posted on by Ravi Shankar

RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new long-term efficacy and safety data from the Company’s ongoing Transform-HTN open-label extension trial of the aldosterone synthase inhibitor lorundrostat will be featured in a late-breaking science presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL.

Details for the Presentation:

Title: Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel
Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
 
Presenter: Manish Saxena MBBS, Deputy Clinical Co-Director of Queen Mary
University of London’s William Harvey Heart Centre, and Hypertension
Specialist at Barts Health NHS Trust
 
Session Time: Sunday, November 8, 3:30 pm CT
 
Session Title: Old Meds, New Meds and BP Goals: Optimizing Antihypertensive
Therapy
 
Session Location: Learning Studio 2, Science and Technology Hall, South Hall
 

About Transform-HTN

Transform-HTN (NCT05968430) is a global open-label extension trial designed to assess the safety, efficacy and tolerability of lorundrostat in participants with hypertension, and includes participants who completed one of three eligible parent studies (Advance-HTN, Launch-HTN or Explore-CKD). Eligible participants were enrolled in the open-label extension study, with a primary endpoint of the change in automated office systolic blood pressure.

About Hypertension
Having sustained, elevated blood pressure (BP) (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertensive patients achieve their BP goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Lorundrostat

Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as CKD, OSA and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.

Mineralys has completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The clinical program includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Forward-Looking Statements

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and include, but are not limited to, statements regarding the potential therapeutic benefits of lorundrostat. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys’ business, including, without limitation: any delays in the Food and Drug Administration’s (FDA) review of Mineralys’ accepted new drug application (NDA), including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of Mineralys’ NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys may not be able to reach agreement on the proposed termination of its license agreement with Tanabe on its expected timeframe, or at all; Mineralys’ future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys’ dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys’ ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; Mineralys’ reliance on its exclusive license with Tanabe to provide Mineralys with intellectual property rights to develop and commercialize lorundrostat; and other risks described in Mineralys’ filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com

Posted in UncategorizedTagged

Zscaler to Host Investor Day on October 6

Posted on by Ravi Shankar

SAN JOSE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the cybersecurity platform for the AI era, today announced that it will host its Investor Day in New York City on Tuesday, October 6, 2026, at 8:30 a.m. Eastern Time. The half-day event will feature presentations from members of Zscaler’s leadership team on the company’s vision, strategy, long-term growth drivers, and financial outlook.

Registration for the live webcast can be found at https://ir.zscaler.com/events/event-details/zscaler-investor-day-2026. A replay will be available on Zscaler’s Investor Relations website after the event concludes.

About Zscaler
Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange™️ platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across 200+ public data centers globally and thousands of private sites at the edge, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Media Contact
Nick Gonzalez
press@zscaler.com

Investor Relations Contact:
Kim Watkins
ir@zscaler.com

Posted in UncategorizedTagged

Casella Releases 2026 Sustainability Report Highlighting Growth and Measurable Progress

Posted on by Ravi Shankar

RUTLAND, Vt., Sept. 23, 2026 (GLOBE NEWSWIRE) — Casella Waste Systems, Inc. (Nasdaq: CWST) (“Casella”), a regional solid waste, recycling, and resource management services company, today released its 2026 Sustainability Report, highlighting how continued focus and investment in its employees, infrastructure and services is driving measurable environmental and operating performance.

“As Casella continues to grow, we are creating more opportunities to invest in our team and infrastructure, and deliver sustainable solutions to some of society’s most complex waste and resource management challenges,” said Ned Coletta, President and CEO of Casella Waste Systems, Inc. “Strong environmental performance and strong operating performance go hand-in-hand, creating an alignment between environmental and economic sustainability.”

The report highlights progress toward Casella’s 2030 Sustainability Goals, including several significant results:

  • More resources recovered: Casella and its customers now recover more than 1.6 million tons of material annually, an increase of more than 500,000 tons since 2019.
  • Greater climate benefit: For every ton of greenhouse gas emitted through Casella’s operations, the company estimates its services prevent 5.7 tons of emissions elsewhere in the economy through recycling, renewable energy and carbon sequestration, surpassing its previously established 2030 goal of 5.0.
  • Stronger communities: Casella employees contributed more than 24,000 volunteer hours in 2025, a 90 percent increase from the prior year.

The report also details continued investments in safety programs, recycling infrastructure, renewable energy, fleet efficiency, employee training and development, and technologies designed to improve safety and environmental performance.

“Our 2030 Sustainability Goals give us clear measures of where we want to go, and the progress we are making gives us confidence in our ability to get there,” Coletta said. “We also recognize that our work is never finished. As new opportunities and challenges emerge each day, we remain committed to having a positive impact on the world around use while driving value for our shareholders.”

The 2026 Sustainability Report is available at www.casella.com/sustainability

Sustainability Report Cover

About Casella Waste Systems, Inc.

Casella Waste Systems, Inc., headquartered in Rutland, Vermont, provides resource management expertise and services to residential, commercial, municipal, institutional and industrial customers, primarily in the areas of solid waste collection and disposal, transfer, recycling and organics services in the eastern United States. For more information, visit www.casella.com.

Safe Harbor Statement

Certain matters discussed in this press release, including, but not limited to, the statements regarding the Company’s intentions, beliefs or current expectations concerning its sustainability goals and commitments and anticipated actions to meet such goals and commitments, and the Company’s progress towards, and achievement of, its sustainability strategy and vision, are “forward looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified as such by the context of the statements, including but not limited to words such as “believe,” “expect,” “anticipate,” “plan,” “may,” “would,” “intend,” “estimate,” “will,” “guidance” and other similar expressions, whether in the negative or affirmative. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management’s beliefs and assumptions. The Company cannot provide assurance that it actually will achieve the plans, intentions, expectations or guidance disclosed in the forward-looking statements made. Such forward-looking statements, and all phases of the Company’s operations, involve a number of risks and uncertainties, any one or more of which could cause actual results to differ materially from those described in its forward-looking statements. Such risks and uncertainties include or relate to, among other things, the following: the ability to improve the Company’s safety performance; the ability to increase the amount of recyclables processed or other resources managed; the impact of changes to, or new, statutory, regulatory and legal requirements; the ability to improve the Company’s fuel efficiency; the ability to further reduce the Company’s carbon footprint; and the amount of the Company’s giving in its communities. There are a number of other important risks and uncertainties that could cause the Company’s actual results to differ materially from those indicated by such forward-looking statements. These additional risks and uncertainties include, without limitation, those detailed in Item 1A, “Risk Factors” in the Company’s Form 10-K for the fiscal year ended December 31, 2025 and in the Company’s Form 10-Q for the quarterly period ended June 30, 2026, and in other filings that the Company may make with the Securities and Exchange Commission in the future. The Company undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Us

Media Relations 
Jeff Weld
Vice President of Communications
(802) 772-2234		 Investor Relations 
Henry Baby, CFA
Vice President of Investor Relations and Finance
(802) 417-3841

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/95efedb7-241d-46f5-81ab-dc6ff63f3992

Posted in UncategorizedTagged

Zymeworks Completes Acquisition of Theravance Biopharma

Posted on by Ravi Shankar
  • Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows.

Zymeworks will host a conference call with investors and the general public at 8:30 am ET on Monday, September 28, to discuss the final transaction details of the acquisition. Dial-in details and webcast link are available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations. A replay of the webcast will be available within 24 hours following the conclusion of the call and will remain archived for a limited period.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks’ asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable Zymeworks to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated benefits of the acquisition of Theravance Biopharma; the anticipated benefits of the financing in connection with the closing of the acquisition; anticipated milestone payments; completion of Theravance’s previously announced organizational restructuring; Zymeworks’ flexibility to invest in its R&D pipeline and pursue strategic opportunities while returning capital to stockholders; future growth of YUPELRI® sales and future royalty payments; contingent milestone payments due to Theravance Biopharma from the sale of Theravance Biopharma’s TRELEGY® royalty interests; Zymeworks’ expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks’ and its partners’ clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, or the negative version of these words and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct.

Factors that could cause Zymeworks’ actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: financial closing procedures, final adjustments, and other developments; risks related to the financing in connection with the closing of the acquisition; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; uncertainties regarding the commercial success of YUPELRI® and TRELEGY®; the anticipated benefits of the acquisition may not be realized or will not be realized within the expected time period; TRELEGY® may not achieve anticipated sales resulting in sales milestones not being met; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; Ziihera® may not be successfully commercialized; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the U.S. Securities and Exchange Commission and System for Electronic Document Analysis and Retrieval+ (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com

Posted in UncategorizedTagged

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Posted on by Ravi Shankar

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product

Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient

MARIETTA, Ga., Sept. 23, 2026 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation challenging the U.S. Food and Drug Administration’s (“FDA”) regulatory classification of AXIOFILL, the Company’s human placental-derived extracellular matrix particulate product.

The Court vacated FDA’s determination that AXIOFILL is not a Section 361 HCT/P because it is more than minimally manipulated and FDA’s determination that AXIOFILL should be classified as a biological product rather than a medical device. The Court remanded both matters to FDA for further consideration consistent with its order.

“This ruling favorably addresses the central issues of this matter. We are pleased the Court found that the FDA erred in its interpretation of the minimal-manipulation regulation and that the agency did not adequately explain the reasoning behind its divergent classification of AXIOFILL compared with similar products available on the market,” stated Joseph H. Capper, Chief Executive Officer of MIMEDX. “We continue to believe that AXIOFILL meets the requirements for classification as a Section 361 HCT/P, and we look forward to engaging constructively with FDA as it reconsiders the matter consistent with the Court’s order.   Since its launch in 2022, AXIOFILL has demonstrated an impeccable safety profile and has helped countless patients navigate the surgical healing process.”

In addressing whether AXIOFILL qualifies as a Section 361 HCT/P, the Court held that FDA had incorrectly interpreted its minimal-manipulation regulation by focusing on the placental disc’s function in the donor—specifically, its function as a selective barrier between the fetal and maternal circulatory systems. The Court concluded that the applicable regulation instead requires FDA to consider the original characteristics of the tissue that are relevant to its utility for reconstruction, repair or replacement in the recipient.

The Court also vacated FDA’s determination that to the extent AXIOFILL is not a Section 361 HCT/P, it is a biological product rather than a device. The Court found that FDA had classified other commercially available human-derived particulate products, similar to AXIOFILL, as medical devices without adequately explaining why AXIOFILL should be treated differently.   The Court concluded that FDA’s classification of AXIOFILL as a biological product was “arbitrary and capricious” because the agency had not provided “a reasonable explanation or record of evidence” supporting this disparate treatment.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

Posted in UncategorizedTagged

Five Below Appoints Scott Settersten to its Board of Directors

Posted on by Ravi Shankar

PHILADELPHIA, PA, Sept. 23, 2026 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ: FIVE), the trend-right, extreme-value brand for the kid and the kid in all of us, today announced the appointment of Scott Settersten, former Chief Financial Officer of Ulta Beauty, to its Board of Directors and the Audit Committee of its Board of Directors, effective September 21, 2026. In connection with Mr. Settersten’s appointment, Five Below’s Board increased to ten directors.

“Scott is a highly respected finance leader with a proven track record of scaling a high-growth retail business while maintaining strong financial discipline,” said Mike Devine, Chair of the Five Below Board. “His deep financial and operational expertise will be a valuable addition to our Board, and we look forward to drawing on Scott’s experience as we execute on our significant growth opportunity and drive long-term value for our stakeholders.”

Mr. Settersten served as the Chief Financial Officer of Ulta Beauty from 2012 until his retirement in March 2024, where he oversaw the company’s finance, accounting, tax, treasury, procurement, internal audit, investor relations, loss prevention and real estate teams. Mr. Settersten also spent 15 years with PricewaterhouseCoopers LLP as a certified public accountant in the assurance and risk management practices. In addition, he served as a director and member of the audit committee of Kimball International from July 2020 to June 2023.

“I am honored to join the Five Below Board at such an exciting time in the company’s evolution,” said Mr. Settersten. “Five Below is one of the most compelling growth stories in retail with a unique value proposition and target customer,” Mr. Settersten continued. “I look forward to working with the Board and leadership team to build on the company’s momentum and execute its long-term growth strategy to create lasting value for shareholders.”

About Five Below:
Five Below is a leading growth retailer offering trend-right, extreme value, high-quality products loved by the kid and the kid in all of us. We believe life is better when customers are free to “let go & have fun” in an amazing experience filled with unlimited possibilities. With most items priced between $1 and $5 and some extreme value items priced beyond $5, Five Below makes it easy to say YES! to the newest, coolest stuff across awesome Five Below worlds: Candy, Style, Party, Room, Create, Tech, Sports and New & Now. Founded in 2002 and headquartered in Philadelphia, Pennsylvania, Five Below today has over 2,000 stores in 47 states. For more information, please visit www.fivebelow.com or follow @fivebelow on TikTok, Instagram, Facebook, and YouTube.

Investor Contact:
Five Below, Inc.
Christiane Pelz, Vice President, Investor Relations
InvestorRelations@fivebelow.com

Posted in UncategorizedTagged

ATN Board Declares Quarterly Dividend

Posted on by Ravi Shankar

BEVERLY, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) — ATN International, Inc. (Nasdaq: ATNI) announced that its Board of Directors has declared a quarterly dividend of $0.29 per share, payable on October 9, 2026, on all common shares outstanding to stockholders of record as of October 3, 2026.

About ATN

ATN International, Inc. (Nasdaq: ATNI), headquartered in Beverly, Massachusetts, is a provider of digital infrastructure and communications services in the United States and internationally, including the Caribbean region, with a focus on rural and remote markets with a growing demand for infrastructure investments. The Company’s operating subsidiaries today primarily provide: (i) advanced wireless and wireline connectivity to residential, business and government customers, including a range of high-speed Internet and data services, fixed and mobile wireless solutions, and video and voice services; and (ii) carrier and enterprise communications services, such as terrestrial and submarine fiber optic transport, and communications tower facilities. For more information, please visit www.atni.com. 

Company Contact:   Investor Relations Contact:
Michele Satrowsky   Joe Noyons or Kelley Buchhorn
SVP, Head of IR & Treasury   Three Part Advisors, LLC
ir@atni.com   jnoyons@threepa.com; kbuchhorn@threepa.com
     

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.